tetano
Editor, Senior Moderator
Infect Dis Ther
. 2020 Sep 20;1-14.
doi: 10.1007/s40121-020-00341-2. Online ahead of print.
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Danyal Ibrahim[SUP] 1 [/SUP], Latha Dulipsingh[SUP] 2 [/SUP], Lisa Zapatka[SUP] 1 [/SUP], Reginald Eadie[SUP] 1 [/SUP], Rebecca Crowell[SUP] 3 [/SUP], Kendra Williams[SUP] 3 [/SUP], Dorothy B Wakefield[SUP] 3 [/SUP], Lisa Cook[SUP] 2 [/SUP], Jennifer Puff[SUP] 2 [/SUP], Syed A Hussain[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have risen to more than 27,000,000 worldwide and more than 885,000 people have died. Currently, no cure or standard treatment for COVID-19 exists. We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19.
Methods: Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge.
Results: Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in the disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p < 0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed.
Conclusions: Our results suggest that convalescent plasma with adequate anti-SARS-CoV-2 antibody titer is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.
Trial registration: ClinicalTrials.gov. Identifier, NCT04343261, IND #19805.
Keywords: Adult respiratory distress syndrome; COVID-19; COVID-19 serotherapy; Hospital mortality; Length of stay; Phase II clinical trial; Plasma; Prospective studies; Severe acute respiratory syndrome coronavirus 2; Ventilation.
. 2020 Sep 20;1-14.
doi: 10.1007/s40121-020-00341-2. Online ahead of print.
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Danyal Ibrahim[SUP] 1 [/SUP], Latha Dulipsingh[SUP] 2 [/SUP], Lisa Zapatka[SUP] 1 [/SUP], Reginald Eadie[SUP] 1 [/SUP], Rebecca Crowell[SUP] 3 [/SUP], Kendra Williams[SUP] 3 [/SUP], Dorothy B Wakefield[SUP] 3 [/SUP], Lisa Cook[SUP] 2 [/SUP], Jennifer Puff[SUP] 2 [/SUP], Syed A Hussain[SUP] 1 [/SUP]
Affiliations
- PMID: 32983830
- PMCID: PMC7502154
- DOI: 10.1007/s40121-020-00341-2
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have risen to more than 27,000,000 worldwide and more than 885,000 people have died. Currently, no cure or standard treatment for COVID-19 exists. We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19.
Methods: Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge.
Results: Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in the disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p < 0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed.
Conclusions: Our results suggest that convalescent plasma with adequate anti-SARS-CoV-2 antibody titer is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.
Trial registration: ClinicalTrials.gov. Identifier, NCT04343261, IND #19805.
Keywords: Adult respiratory distress syndrome; COVID-19; COVID-19 serotherapy; Hospital mortality; Length of stay; Phase II clinical trial; Plasma; Prospective studies; Severe acute respiratory syndrome coronavirus 2; Ventilation.